ImpediMed

ImpediMed Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of ImpediMed (IPD.AX) as of Nov 2, 2026 is 80.42 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 63.02 % — a change of 27.61% (higher).

Cash Conversion

80.42 %

YoY

27.61%

Last updated:

Cash Conversion Rate (OCF/Net Income) of ImpediMed is 2026 80.42 % . Cash Conversion Rate (OCF/Net Income) of ImpediMed was 2025 63.02 % . It decreases by 27.61% higher compared to the previous year.

The ImpediMed Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
81.63 AUD
Jan 1, 2020
89.90 AUD
Jan 1, 2021
64.03 AUD
Jan 1, 2022
78.82 AUD
Jan 1, 2023
87.95 AUD
Jan 1, 2024
89.89 AUD
Jan 1, 2025
63.02 AUD
Jan 1, 2026
80.42 AUD
The ImpediMed Cash Conversion history
YEARCash ConversionYoY
80.42 %+27.61%
63.02 %-29.89%
89.89 %+2.20%
87.95 %+11.59%
78.82 %+23.09%
64.03 %-28.78%
89.90 %+10.13%
81.63 %-5.18%
86.09 %-7.16%
92.73 %+7.44%
86.30 %+18.72%
72.70 %-15.19%
85.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Cash Conversion Rate (OCF/Net Income) of ImpediMed is 80.42 % in 2026.

Cash Conversion Rate (OCF/Net Income) of ImpediMed changed from 63.02 % to 80.42 %, representing a 27.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s ImpediMed with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ImpediMed

All Key Metrics — ImpediMed